<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286272</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02625</org_study_id>
    <secondary_id>NCI-2011-02625</secondary_id>
    <secondary_id>CALGB-50904</secondary_id>
    <secondary_id>CDR0000694298</secondary_id>
    <secondary_id>CALGB-50904</secondary_id>
    <secondary_id>CALGB-50904</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT01286272</nct_id>
  </id_info>
  <brief_title>Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride
      with or without bortezomib works in treating patients with untreated follicular non-Hodgkin
      lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different
      ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
      the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may
      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
      Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It
      is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with
      bortezomib in treating patients with follicular non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the complete response (CR) rate in newly diagnosed, untreated follicular
      lymphoma patients receiving 6 cycles of ofatumumab-bendamustine (bendamustine hydrochloride)
      (ARM A) and 6 cycles of ofatumumab, bortezomib, and bendamustine (ARM B) using International
      Harmonization Project Response Criteria.

      SECONDARY OBJECTIVES:

      I. To determine progression-free survival (PFS) of patients with untreated follicular
      lymphoma after 6 cycles of ofatumumab-bendamustine (ARM A) followed by maintenance ofatumumab
      and after 6 cycles of ofatumumab, bortezomib, and bendamustine followed by maintenance
      ofatumumab and bortezomib (ARM B).

      II. To determine the toxicity profile of ofatumumab and bendamustine and ofatumumab,
      bortezomib, and bendamustine in patients with untreated high-risk follicular lymphoma.

      III. To determine if changes in both qualitative and semi-quantitative fludeoxyglucose
      (FDG)-positron-emission tomography (PET) findings at baseline, after cycle 2 (day 32-35), and
      at end of therapy (6-8 weeks after the last cycle of induction chemotherapy but prior to
      maintenance therapy) with ofatumumab-bendamustine and ofatumumab, bortezomib, and
      bendamustine correlate with response and PFS in patients with high-risk follicular lymphoma.

      IV. To assess if a combinatorial approach using both qualitative and semi-quantitative
      changes in FDG-PET and computed tomography (CT) or magnetic resonance imaging (MRI) studies
      at baseline, after cycle 2 (day 32-35), and at end of therapy (6-8 weeks after the last cycle
      of induction chemotherapy prior to maintenance therapy) would result in a higher predictive
      value for response and PFS in patients with high-risk follicular lymphoma.

      V. To correlate all molecular parameters with FDG-PET parameters in determination of response
      and PFS.

      VI. To correlate pre-treatment single nucleotide polymorphisms with response and PFS
      following ofatumumab-bendamustine and ofatumumab, bortezomib, and bendamustine therapy in
      patients with untreated high-risk follicular lymphoma.

      VII. To correlate cluster of differentiation (CD)-68, B-cell chronic lymphocytic leukemia
      (CLL)/lymphoma (bcl)-2, marker of proliferation Ki-67 (Ki-67), forkhead box P3 (FOXP3),
      activated cytotoxic T-cells, lymphoma-associated macrophages (LAM), melanoma associated
      antigen (mutated) 1 (MUM1), CD10, nuclear v-rel avian reticuloendotheliosis viral oncogene
      homolog A (p65) and v-rel avian reticuloendotheliosis viral oncogene homolog C (cREL)
      subunits of nuclear factor of kappa light polypeptide gene enhancer in B-cells (NFkB), and
      selected genetic translocations by fluorescent in situ hybridization (FISH) analysis (such as
      Bcl-2 and Bcl-6) with response and PFS in patients receiving initial therapy for high-risk
      follicular lymphoma.

      VIII. To determine whether immune gene signatures previously identified as prognostic factors
      in follicular lymphoma can be applied to paraffin-embedded tissues in ofatumumab and
      bendamustine or ofatumumab, bendamustine, and bortezomib treated patients; evaluate
      micro-ribonucleic acid (RNA) signatures associated with these gene signatures and outcome.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A:

      INDUCTION: Patients receive ofatumumab intravenously (IV) over 2-8 hours on day 1 and
      bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35
      days for up to 6 courses. Patients without disease progression continue on to maintenance
      therapy.

      MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive
      ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.

      ARM B:

      INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride
      IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or subcutaneously
      (SC) on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients
      without disease progression continue on to maintenance therapy.

      MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive
      ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8,
      15, and 22. Treatment repeats every 56 days for up to 4 courses.

      After completion of study treatment, patients are followed up every 4 months for 2 years and
      then every 6 months for up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2011</start_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>From date of randomization until patient stops treatment for any reason, up to 484 days post-randomization</time_frame>
    <description>A complete response was defined using International Harmonization Project Response Criteria as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. If the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
The complete response (CR) rate was calculated in newly diagnosed untreated follicular lymphoma patients receiving 6 cycles of ofatumumab-bendamustine (ARM A) and 6 cycles of ofatumumab, bortezomib, and bendamustine (ARM B).
The complete response rate was calculated as the number of patients with a complete response divided by the number of patients eligible for evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PFS rates (percentages) at 1, 2, ,3 and 4 years are defined as the percentage of patients who are alive and progression-free at the respective time points. The p-values of the log-rank test will be calculated to compare PFS between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Experienced Grade 3+ Hematologic and Non-hematologic Adverse Events at Least Possibly Related to Treatment</measure>
    <time_frame>From date of randomization until patient stops treatment for any reason, up to 484 days post-randomization</time_frame>
    <description>The number of patients who experienced grade 3+ hematologic and non-hematologic adverse events at least possibly related to treatment assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pre-treatment Single Nucleotide Polymorphisms (SNP)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The PFS will be compared among the three genotype groups of each SNP using the log-rank tests. A maxtype test will be used by taking the maximum value of the log-rank tests under dominant, recessive, and proportional hazard model. The critical value (or p-value) of the max test will be obtained by a permutation method. No multiple testing adjustment may be applied because of the small sample size.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemical (IHC) Markers</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The IHC markers will be correlated with response (using the two-sample t-test) and PFS (using the Cox regression method) data. No multiple testing adjustment will be applied because of the small sample size.</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictive Value of Fludeoxyglucose-positron-emission Tomography</measure>
    <time_frame>Up to 36-38 weeks (6-8 weeks after course 6, day 1 after last course of induction chemotherapy)</time_frame>
    <description>The ratio will be correlated with response (using the two-sample t-test) and PFS (using the Cox regression method) data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Ann Arbor Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Ann Arbor Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Ann Arbor Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Ann Arbor Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Ann Arbor Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Ann Arbor Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Grade 3a Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <other_name>Bendamustin Hydrochloride</other_name>
    <other_name>Bendeka</other_name>
    <other_name>Cytostasan Hydrochloride</other_name>
    <other_name>Levact</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>SyB L-0501</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG-PET</description>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <other_name>Arzerra</other_name>
    <other_name>GSK1841157</other_name>
    <other_name>HuMax-CD20</other_name>
    <other_name>HuMax-CD20, 2F2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography with Radiolabeled Targeting Agent</intervention_name>
    <description>Undergo FDG-PET</description>
    <arm_group_label>Arm A (ofatumumab, bendamustine hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)</arm_group_label>
    <other_name>Positron Emission Tomography with Radiolabeled Targeting Agents</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed follicular non-Hodgkin lymphoma, World Health Organization
             (WHO) classification grade 1, 2, or 3a (&gt; 15 centroblasts per high-power field with
             centrocytes present)

               -  Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they
                  may be submitted in conjunction with nodal biopsies

               -  Fine-needle aspirates are not acceptable

               -  Failure to submit pathology within 60 days of patient registration will be
                  considered a major protocol violation

          -  Patients must have at least one of the following indicators of poor risk disease:

               -  &gt;= 3 risk factors by the Follicular Lymphoma International Prognostic Index, or 2
                  risk factors by the Follicular Lymphoma International Prognostic Index and at
                  least one bulky mass or lymph node &gt; 6 cm in size

               -  Follicular Lymphoma International Prognostic Index (FLIPI score):

                    -  Age &gt; 60 years

                    -  Involvement of &gt; 4 nodal sites

                    -  Stage III-IV disease

                    -  Hemoglobin &lt; 12.0 g/dL

                    -  Lactate dehydrogenase (LDH) &gt; upper limit of normal (ULN)

                         -  0-1 of the above risk factors: low risk

                         -  2 risk factors: intermediate risk

                         -  &gt;= 3 risk factors: poor risk

          -  No prior cytotoxic chemotherapy, radiotherapy, immunotherapy, or radioimmunotherapy

          -  No corticosteroids are permitted, except for maintenance therapy for a non-malignant
             disease or to prevent treatment-related ofatumumab reactions (maintenance therapy dose
             must not exceed 20 mg/day prednisone or equivalent)

          -  Measurable disease must be present either on physical examination or imaging studies;
             non-measurable disease alone is not acceptable; any tumor mass &gt; 1 cm is acceptable;
             lesions that are considered non-measurable include the following:

               -  Bone lesions

               -  Leptomeningeal disease

               -  Ascites

               -  Pleural/pericardial effusion

               -  Inflammatory breast disease

               -  Lymphangitis cutis/pulmonis

               -  Bone marrow involvement (involvement by non-Hodgkin lymphoma should be noted)

          -  Patients must have no known central nervous system (CNS) involvement by lymphoma

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must be non-pregnant and non-nursing; pregnant or nursing patients may not be
             enrolled; women of childbearing potential must have a negative serum or urine
             pregnancy test within 14 days prior to registration; in addition, women and men of
             childbearing potential must commit to use an effective form of contraception
             throughout their participation in this study; appropriate methods of birth control
             include abstinence, oral contraceptives, implantable hormonal contraceptives
             (Norplant), or double barrier method (diaphragm plus condom)

          -  Patients with human immunodeficiency virus (HIV) infection are eligible; patients with
             HIV infection must meet the following: no evidence of co-infection with hepatitis B or
             C; CD4+ count &gt; 400/ul; no evidence of resistant strains of HIV; on anti-HIV therapy
             with an HIV viral load &lt; 50 copies HIV RNA/mL; no history of acquired immunodeficiency
             syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to
             overlapping toxicity with chemotherapy

          -  Patients must have no evidence of active hepatitis B or C infection (i.e., no positive
             serology for anti-hepatitis B core [HBc] or anti-hepatitis C virus [HCV] antibodies);
             hepatitis B virus (HBV) seropositive patients (hepatitis B surface antigen [HBsAg] +)
             are eligible if HBV deoxyribonucleic acid (DNA) is undetectable at baseline and they
             are closely monitored for evidence of active HBV infection by HBV DNA testing at each
             treatment cycle; after completing treatment, HBsAg + patients must be monitored by HBV
             DNA testing every 2 months for 6 months post-treatment, while continuing lamivudine

          -  Granulocytes &gt;= 1,000/uL

          -  Platelet count &gt;= 75,000/uL

          -  Creatinine =&lt; 2.0 mg/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x upper
             limits of normal (ULN)

          -  Bilirubin =&lt; 2 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristie A Blum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance for Clinical Trials in Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pali Momi Medical Center</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Cancer Center - Pearlridge</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care Inc-POB II</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Straub Clinic and Hospital</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care Inc-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuakini Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Medical Center</name>
      <address>
        <city>Kailua</city>
        <state>Hawaii</state>
        <zip>96734</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilcox Memorial Hospital and Kauai Medical Clinic</name>
      <address>
        <city>Lihue</city>
        <state>Hawaii</state>
        <zip>96766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center-Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weiss Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Illinois - Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem-Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology Inc-Parkview</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Cancer Center Day Road</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology PC-Mishawaka</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology PC-Westville</name>
      <address>
        <city>Westville</city>
        <state>Indiana</state>
        <zip>46391</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Associates at Mercy Medical Center</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penobscot Bay Medical Center</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension Saint John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital - Healtheast</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic - Saint Louis Park</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center - Bolivar</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benefis Healthcare- Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York-East Syracuse</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health NCORP</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health/Center for Advanced Medicine</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Oncology-Kinston</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annie Penn Memorial Hospital</name>
      <address>
        <city>Reidsville</city>
        <state>North Carolina</state>
        <zip>27320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iredell Memorial Hospital</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital North</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Centers-Maumee</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Charles Hospital</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Flower Hospital</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Saint Anne Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Centers-Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group PC-Robert Packer Hospital</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>October 12, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 10, 2019</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01286272/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One hundred thirty five patients registered to this trial. However, 3 patients cancelled prior to receiving any study treatment and were excluded from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
          <description>INDUCTION: Patients receive: &gt; 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy. &gt;
&gt; MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
          <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy. &gt;
&gt; MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible after beginning treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients that were eligible for endpoint analysis were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
          <description>INDUCTION: Patients receive: &gt; 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy. &gt;
&gt; MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
          <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy. &gt;
&gt; MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="25" upper_limit="87"/>
                    <measurement group_id="B2" value="61.5" lower_limit="31" upper_limit="81"/>
                    <measurement group_id="B3" value="61" lower_limit="25" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response Rate</title>
        <description>A complete response was defined using International Harmonization Project Response Criteria as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. If the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
The complete response (CR) rate was calculated in newly diagnosed untreated follicular lymphoma patients receiving 6 cycles of ofatumumab-bendamustine (ARM A) and 6 cycles of ofatumumab, bortezomib, and bendamustine (ARM B).
The complete response rate was calculated as the number of patients with a complete response divided by the number of patients eligible for evaluation.</description>
        <time_frame>From date of randomization until patient stops treatment for any reason, up to 484 days post-randomization</time_frame>
        <population>All patients that were eligible for response assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
            <description>INDUCTION: Patients receive:
300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
            <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <description>A complete response was defined using International Harmonization Project Response Criteria as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. If the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
The complete response (CR) rate was calculated in newly diagnosed untreated follicular lymphoma patients receiving 6 cycles of ofatumumab-bendamustine (ARM A) and 6 cycles of ofatumumab, bortezomib, and bendamustine (ARM B).
The complete response rate was calculated as the number of patients with a complete response divided by the number of patients eligible for evaluation.</description>
          <population>All patients that were eligible for response assessment were included in this analysis.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".621"/>
                    <measurement group_id="O2" value=".597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PFS rates (percentages) at 1, 2, ,3 and 4 years are defined as the percentage of patients who are alive and progression-free at the respective time points. The p-values of the log-rank test will be calculated to compare PFS between the two arms.</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
            <description>INDUCTION: Patients receive:
300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
            <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PFS rates (percentages) at 1, 2, ,3 and 4 years are defined as the percentage of patients who are alive and progression-free at the respective time points. The p-values of the log-rank test will be calculated to compare PFS between the two arms.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PFS at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="88.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="84.8" lower_limit="76.2" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" lower_limit="70.8" upper_limit="91.0"/>
                    <measurement group_id="O2" value="75.6" lower_limit="65.2" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS at 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" lower_limit="53.9" upper_limit="80.7"/>
                    <measurement group_id="O2" value="67.1" lower_limit="55.5" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS at 4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="43.2" upper_limit="75.9"/>
                    <measurement group_id="O2" value="64.7" lower_limit="52.8" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8457</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Experienced Grade 3+ Hematologic and Non-hematologic Adverse Events at Least Possibly Related to Treatment</title>
        <description>The number of patients who experienced grade 3+ hematologic and non-hematologic adverse events at least possibly related to treatment assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
        <time_frame>From date of randomization until patient stops treatment for any reason, up to 484 days post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
            <description>INDUCTION: Patients receive:
300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
            <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Experienced Grade 3+ Hematologic and Non-hematologic Adverse Events at Least Possibly Related to Treatment</title>
          <description>The number of patients who experienced grade 3+ hematologic and non-hematologic adverse events at least possibly related to treatment assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pre-treatment Single Nucleotide Polymorphisms (SNP)</title>
        <description>The PFS will be compared among the three genotype groups of each SNP using the log-rank tests. A maxtype test will be used by taking the maximum value of the log-rank tests under dominant, recessive, and proportional hazard model. The critical value (or p-value) of the max test will be obtained by a permutation method. No multiple testing adjustment may be applied because of the small sample size.</description>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunohistochemical (IHC) Markers</title>
        <description>The IHC markers will be correlated with response (using the two-sample t-test) and PFS (using the Cox regression method) data. No multiple testing adjustment will be applied because of the small sample size.</description>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Predictive Value of Fludeoxyglucose-positron-emission Tomography</title>
        <description>The ratio will be correlated with response (using the two-sample t-test) and PFS (using the Cox regression method) data.</description>
        <time_frame>Up to 36-38 weeks (6-8 weeks after course 6, day 1 after last course of induction chemotherapy)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected systematically after each cycle, up to 10 cycles. Cycles 1-6 were up to 35 days and cycles 7-10 were up to 56 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Ofatumumab, Bendamustine Hydrochloride)</title>
          <description>INDUCTION: Patients receive:
300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Ofatumumab, Bendamustine Hydrochloride, Bortezomib)</title>
          <description>INDUCTION: Patients receive 300 mg ofatumumab IV over 2-8 hours on day 1, cycle1 and 1000 mg ofatumumab IV on day 1, cycle 2-6 and 90 mg/m2 bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive 1000 mg ofatumumab IV over 2-8 hours on day 1 and 1.6 mg/m2 bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="141" subjects_affected="30" subjects_at_risk="67"/>
                <counts group_id="E2" events="149" subjects_affected="40" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="27" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="71" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E2" events="130" subjects_affected="34" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="22" subjects_at_risk="67"/>
                <counts group_id="E2" events="116" subjects_affected="39" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="28" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="28" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="125" subjects_affected="39" subjects_at_risk="67"/>
                <counts group_id="E2" events="192" subjects_affected="55" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="57" subjects_affected="33" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="32" subjects_affected="18" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="241" subjects_affected="49" subjects_at_risk="67"/>
                <counts group_id="E2" events="207" subjects_affected="46" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="42" subjects_affected="17" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="67"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cecal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="75" subjects_affected="20" subjects_at_risk="67"/>
                <counts group_id="E2" events="23" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="61" subjects_affected="24" subjects_at_risk="67"/>
                <counts group_id="E2" events="52" subjects_affected="14" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="42" subjects_affected="14" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="284" subjects_affected="48" subjects_at_risk="67"/>
                <counts group_id="E2" events="218" subjects_affected="44" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="130" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E2" events="119" subjects_affected="35" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="140" subjects_affected="32" subjects_at_risk="67"/>
                <counts group_id="E2" events="136" subjects_affected="35" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="198" subjects_affected="37" subjects_at_risk="67"/>
                <counts group_id="E2" events="183" subjects_affected="43" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" events="54" subjects_affected="18" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="135" subjects_affected="28" subjects_at_risk="67"/>
                <counts group_id="E2" events="78" subjects_affected="25" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="42" subjects_affected="15" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="26" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased cervical spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="22" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="43" subjects_affected="17" subjects_at_risk="67"/>
                <counts group_id="E2" events="24" subjects_affected="8" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" events="43" subjects_affected="18" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Movements involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Olfactory nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="62" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" events="146" subjects_affected="36" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="47" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="28" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="17" subjects_at_risk="67"/>
                <counts group_id="E2" events="50" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" events="41" subjects_affected="18" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="46" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Erythroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Periorbital edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="48" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" events="51" subjects_affected="25" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="79" subjects_affected="18" subjects_at_risk="67"/>
                <counts group_id="E2" events="42" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristie A. Blum, MD</name_or_title>
      <organization>Alliance for Clinical Trials in Oncology</organization>
      <phone>614-293-8858</phone>
      <email>kristie.blum@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

